It’s developing products for glaucoma and other conditions.
NEW YORK — Biopharmaceutical company Eyenovia Inc. has closed on an initial public offering of 2.73 million shares of common stock.
Eyenovia received $27.3 million in gross proceeds from the offering, according to a press release. The company's common shares are traded on the Nasdaq Capital Market under the ticker symbol "EYEN."
Eyenovia is "a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye," according to the release.
Eyenovia’s pipeline is focused on micro-therapeutics for glaucoma and other eye diseases. The company's website says its technology "will replace outdated dropper technology for improved patient experience and compliance."
Hear What the Industry Thinks About the Ultimate Lens Package by Essilor
Eye care professionals, patients, and Essilor sales consultants shared their feedback on the Ultimate Lens Package. Watch to see why they believe the innovation behind the lens can make the difference for your practice and for your patients. For more information on the Ultimate Lens Package, contact an Essilor Sales Consultant or click here.